While reiterating its 'hold' recommendation on Equasens, Stifel has lowered its target price from €86 to €75, following a business update deemed disappointing, with no growth in the third quarter after only 4% in the second.

The broker points out that this ultimately comes down to two factors: an unfavorable basis for comparison linked to the Ségur digitization program in France, and a significant slowdown in growth in the French pharmacy market.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.